Kiniksa Pharmaceuticals to Present at 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Kiniksa Pharmaceuticals (Nasdaq: KNSA) will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 2:15 p.m. PT (5:15 p.m. ET). A live webcast will be available via the company's Investors website and a replay will be posted approximately 48 hours after the event.
Investors can access the webcast at www.kiniksa.com.
Positive
- None.
Negative
- None.
News Market Reaction – KNSA
In the Jan 8 session, KNSA declined 1.63%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 12 | Investor conference | Neutral | -0.7% | Announcement of Jefferies Global Healthcare Conference presentation and webcast access. |
| Oct 28 | Earnings and portfolio | Positive | -2.9% | Strong Q3 2025 ARCALYST revenue growth, raised guidance, and positive profitability. |
| Oct 23 | Earnings date notice | Neutral | +0.4% | Scheduling of Q3 2025 results call and webcast logistics for investors. |
| Oct 17 | Regulatory designation | Positive | -0.7% | FDA Orphan Drug Designation granted to KPL-387 for pericarditis treatment. |
| Aug 28 | Investor conferences | Neutral | -0.0% | Planned participation in Citi and Wells Fargo healthcare investor conferences. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Investor conference announcements have historically produced minimal price impact, while positive fundamental or clinical updates have previously seen near-term price weakness.
Over the last few months, Kiniksa has mixed operational and investor-relations news. A November 2025 Jefferies conference appearance and August investor conferences had little price effect around their dates. By contrast, strong Q3 2025 financials and portfolio execution reported on Oct 28, 2025, plus an FDA Orphan Drug Designation on Oct 17, 2025, were followed by negative next-day moves. Today’s J.P. Morgan conference notice fits the pattern of routine conference communications rather than a new fundamental catalyst.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LONDON, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that it will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time).
A live webcast of Kiniksa’s presentation will be accessible through the Investors section of the company’s website at www.kiniksa.com. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.
About Kiniksa
Kiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa’s portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. For more information, please visit www.kiniksa.com.
Every Second Counts! ®
Kiniksa Investor & Media Contact
Jonathan Kirshenbaum
(781) 829-3949
jkirshenbaum@kiniksa.com
